OPENING: In an era of media sensationalism, I have come to appreciate good journalism. When it comes to healthcare, my number one choice is STAT News, but I have also found the Financial Times and The Economist to be excellent sources. Below is a summary of an in-depth article from the Finacial Times on Pfizer and their COVID vaccine. It’s beyond damning; it’s a reflection of an industry that values profits above all else.

OPENING: As the NY Times recently reported, obesity is the leading cause of mortality in the United States. Obesity costs the nation $1.72 trillion every year. Although not everyone with type 2 diabetes is overweight, obesity and an inactive lifestyle are two of the most common causes of type 2 diabetes. These things are responsible for about 90% to 95% of diabetes cases in the United States

SUMMARY: AbbVie continues to profit from Americans by repeatedly raising U.S. prices on its widely-used Humira rheumatoid arthritis drug while cutting the price abroad. AbbVie exploits the U.S. patent system to fend off competitors and increased the price of Humira to $77,000 for a year’s supply, while the price of its cancer drug Imbruvica was raised to $181,529 per year.

SUMMARY: Wegovy is selling so well that it’s hard to get at pharmacies. It’s being positioned as an anti-obesity drug, but one study by Novo Nordisk has shown that people who stop taking Wegovy after a few months tend to regain much of their lost weight within a year. In addition, people who lost weight on Wegovy in clinical trials had nutritional counseling and had to stay on a strict diet.

SUMMARY: Now that President Biden’s attempt to lower Medicare drug prices is dead, pharma can get back to business, and their business, of course, is making money. Using social media analytical tools, I was able to determine that there are a lot of outraged voters out there. Politics is broken and is too often about money, not what’s best for people.